Additionally, the 36-month beta value for CRVO is 1.60. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CRVO is 5.35M and currently, short sellers hold a 27.71% ratio of that float. The average trading volume of CRVO on November 27, 2024 was 84.74K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRVO) stock’s latest price update
The stock of CervoMed Inc (NASDAQ: CRVO) has decreased by -8.90 when compared to last closing price of 8.76.Despite this, the company has seen a loss of -20.83% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that – Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected in December 2024 –
CRVO’s Market Performance
CRVO’s stock has fallen by -20.83% in the past week, with a monthly drop of -39.13% and a quarterly drop of -51.01%. The volatility ratio for the week is 10.68% while the volatility levels for the last 30 days are 9.18% for CervoMed Inc The simple moving average for the past 20 days is -29.40% for CRVO’s stock, with a -53.39% simple moving average for the past 200 days.
Analysts’ Opinion of CRVO
Many brokerage firms have already submitted their reports for CRVO stocks, with Chardan Capital Markets repeating the rating for CRVO by listing it as a “Buy.” The predicted price for CRVO in the upcoming period, according to Chardan Capital Markets is $55 based on the research report published on September 18, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CRVO reach a price target of $35. The rating they have provided for CRVO stocks is “Overweight” according to the report published on July 26th, 2024.
Canaccord Genuity gave a rating of “Buy” to CRVO, setting the target price at $50 in the report published on February 15th of the current year.
CRVO Trading at -38.44% from the 50-Day Moving Average
After a stumble in the market that brought CRVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.75% of loss for the given period.
Volatility was left at 9.18%, however, over the last 30 days, the volatility rate increased by 10.68%, as shares sank -40.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.56% lower at present.
During the last 5 trading sessions, CRVO fell by -20.83%, which changed the moving average for the period of 200-days by -42.88% in comparison to the 20-day moving average, which settled at $11.30. In addition, CervoMed Inc saw 4.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRVO starting from ELDER WILLIAM ROBERT, who purchase 1,000 shares at the price of $18.16 back on Aug 27 ’24. After this action, ELDER WILLIAM ROBERT now owns 1,267 shares of CervoMed Inc, valued at $18,160 using the latest closing price.
Stock Fundamentals for CRVO
Current profitability levels for the company are sitting at:
- -1.66 for the present operating margin
- 0.3 for the gross margin
The net margin for CervoMed Inc stands at -1.47. The total capital return value is set at -0.28. Equity return is now at value -43.28, with -39.22 for asset returns.
Currently, EBITDA for the company is -2.17 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 7.15. The receivables turnover for the company is 30.77for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.04.
Conclusion
In conclusion, CervoMed Inc (CRVO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
